Tigecycline (Tygacil, Wyeth Pharmaceuticals, formally GAR-936) is the first glycylcycline antibiotic. It is structurally derived from minocycline but modified to provide a broad spectrum of antibacterial activity and an ability to overcome tetracycline-resistance mechanisms. Tigecycline displays in vitro activity against several Gram-positive, Gram-negative and anaerobic bacteria. It is extensively distributed in tissues. In the USA, it is currently indicated for the treatment of complicated intraabdominal infections (cIAIs) and complicated skin and skin-structure infections (cSSIs). Since US FDA and European Commission approval for these indications (June 2005 and May 2006, respectively), additional experiences with tigecycline have been reported. These include two Phase III clinical trials evaluating tigecycline for hospitalized patients with community-acquired pneumonia, clinical outcome studies of off-label indications and in vitro-susceptibility evaluations for drug-resistant Gram-positive and Gram-negative pathogens.
Expert Rev Anti Infect Ther. 2008;6(5):557-567. © 2008 Expert Reviews Ltd.
No writing assistance was utilized in the production of this manuscript.
Cite this: Establishing the Role of Tigecycline in an era of Antimicrobial Resistance - Medscape - Oct 01, 2008.